Browse grants

National Institutes of Health · Up to $300K

This NIH (R01) opportunity funds basic research into the harmful effects of acute exposure to ultra-potent synthetic opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations, including delayed effects. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $300,000.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R61/R33) phased opportunity funds medical device prototype design and testing, disease-target identification, and assay development for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R33) opportunity funds early-stage translational work to optimize medical device prototypes, develop diagnostic assays, and create research tools for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Up to $350K

This NHLBI Catalyze (R33) opportunity funds rigorous validation of transformative, multi-use platforms or technologies that can advance detection, diagnosis, treatment, or prevention of heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $350,000.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R61/R33) phased opportunity funds target identification and validation plus preliminary product or lead-series identification for small molecules, biologics, and combination products treating heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R33) opportunity funds early-stage translational work to identify and characterize therapeutic candidates and combination products (small molecules and biologics) for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

Environmental Protection Agency · Up to $3M

This EPA program funds assessment and remediation of contaminated Alaska Native Claims Settlement Act lands, plus related community outreach. Eligibility is limited to Alaska Native regional and village corporations, federally recognized Tribes in Alaska, Alaska Native nonprofit associations, and inter-tribal consortia of Alaskan tribal entities. The maximum award is up to about $3,000,000, and proposals are accepted on a rolling basis; applicants are asked to contact program managers first.

National Park Service · Amount varies

This National Park Service opportunity offers Master Cooperative Agreements to participants in the Cooperative Ecosystem Studies Units (CESU) network across listed regions, supporting research, technical assistance, education, and capacity building. Only existing CESU network partners may apply, so applicants must already have joined the network. No specific award amount is provided.

National Institutes of Health · Amount varies

This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of drug, biologic, device, or procedure intervention clinical trials within NIDCR's mission. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH SHINE (R01) opportunity supports innovative basic and early translational research in nonmalignant hematology, relevant to NIDDK, NIA, and NHLBI missions. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIDCR (UH3) opportunity funds competing renewal or competitive revision of ongoing clinical trials already supported by NIDCR; a clinical trial is required. Because it continues existing NIDCR-funded trials, it is effectively limited to current grantees and not open to new projects. It is aimed at research and academic institutions; foreign organizations are not eligible. No specific award amount is stated.

National Institutes of Health · Up to $500K

This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of behavioral and social intervention clinical trials for dental, oral, or craniofacial conditions, with a milestone-driven planning phase before transition to a full trial. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $500,000.

National Institutes of Health · Up to $200K

This NIH ORIP (R21) opportunity funds research to develop, improve, and preserve animal models and related biological materials with broad applicability across multiple NIH institutes; single-disease or single-institute projects are out of scope. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $200,000.

National Institutes of Health · Amount varies

This NIH (R61/R33) opportunity funds discovery and early evaluation of candidate biomarkers for neurological and neuromuscular disorders, requiring preliminary human-sample evaluation. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Up to $500K

This NCI (R01) opportunity funds investigator-initiated studies on the mechanisms by which bariatric surgery affects cancer risk. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.

National Institutes of Health · Amount varies

This NIH award funds research projects developing new technologies to advance biomedical knowledge acquisition, aimed at institutions including HBCUs, Hispanic-serving institutions, and tribal colleges, among others. Foreign organizations and their non-U.S. components are not eligible to apply. No specific dollar amount is listed, and the deadline is not imminent.

National Institutes of Health · Up to $500K

This NIH (R01) opportunity funds development and use of molecular imaging methods to study inflammation in cancer in vivo, encouraging collaboration between cancer biologists and imaging scientists. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds translational research into mood and psychosis symptoms during the menopause transition, examining underlying neurobiological and behavioral mechanisms. It targets research and academic institutions and interdisciplinary research teams, not individuals or typical nonprofits/small businesses. No specific award amount is stated.